The director of this ASX company just made another sizeable share purchase

More insider buying action has failed to prop up the Polynovo share price.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Polynovo shares backtrack 4.6% to $1.14 
  • Polynovo chair, David Williams topped up his holdings through an on-market trade of close to 80,000 shares 
  • Since the beginning of May, Mr Williams has spent around $4.65 million on Polynovo shares 

In a sea of red across the ASX today, the Polynovo Ltd (ASX: PNV) share price is faring no better.

During early afternoon trade, the medical device company's shares are swapping hands at $1.14, down 4.6%.

This comes despite Polynovo announcing another sizeable share purchase from one of its directors.

For context, the All Ordinaries Index (ASX: XAO) is 0.95% in the red to 7,391.9 points.

A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone

Image source: Getty Images

Polynovo insider buying action continues

Following the recent market slump, the company's chair, David Williams has decided to take advantage of the Polynovo share price weakness.

According to its release, Polynovo advised that Mr Williams has bought 79,557 shares at a price of $1.1849 apiece. This was conducted via an on-market trade by Mr Williams' subsidiary, Lawn Views Pty Ltd.

The transaction equates to a value of more than $94,000.

Following the latest purchase, this means that Mr Williams now has over 23.24 million fully paid ordinary Polynovo shares across all holdings.

The latest buy-in reflects that a number of insiders, particularly Mr Williams believe Polynovo shares are trading at bargain levels.

It is worth noting that at the beginning of May, Polynovo shares touched a 52-week low of 83.5 cents.

It's also worth noting that Mr Williams has made a number of purchases since the beginning of May 2022. In fact, he has spent around $4.65 million over that time.

Polynovo share price summary

Despite this month's 19% gain, Polynovo shares have fallen by 55% in the past 12 months.

Year to date, its shares are down roughly 25%.

Based on today's price, Polynovo presides a market capitalisation of approximately $817.18 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman with bright yellow hair wearing a brightly patterned blouse reacts to big news that she's reading on her phone.
Healthcare Shares

Historic: Here's why CSL shares are looking very interesting right now

CSL's yield now rivals a big four bank...

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

4DMedical shares jump 11% as investors cheer major US agreement

4DMedical has landed another commercial foothold in the US.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Healthcare Shares

Which ASX healthcare stock could rise over 100% according to Bell Potter?

Let's see what the broker is saying about this stock this week.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

These 3 ASX healthcare stocks have been crushed in 2026. They could be set for a comeback

CSL is at a 10-year low. Cochlear has fallen 62%. ResMed is down on fears that proved wrong. Are any…

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Should I buy CSL shares in June?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

A man in a business suit holds his hand up to his mouth as though sharing a secret and gives a sly grin.
Healthcare Shares

After CSL's 60% share price crash, insiders are starting to buy

Insiders are buying after a brutal CSL share price fall.

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

At under $100 each, Cochlear shares look like a bargain: Here's why

Cochlear Ltd (ASX: COH) shares have now crashed 63% for the year-to-date.

Read more »

A doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

3 ASX 200 shares I'd buy for the future of healthcare

Healthcare investing often requires patience, but I think the sector can produce some excellent long-term winners.

Read more »